Neogen Chemicals Allots 10 Lakh Equity Shares Worth ₹161 Crore on Preferential Basis
Neogen Chemicals allotted 10,00,000 equity shares at ₹1,610 each, raising ₹161 crore via preferential issue to Cadamba Solutions Private Limited. The company's paid-up capital increased to ₹27.38 crore.
The preferential allotment of ₹161 crore is a significant amount for the company and will increase its equity share capital, potentially impacting its financial structure and shareholder value.
The company successfully raised capital through a preferential allotment, which is generally viewed positively as it strengthens the company's financial position.
Neogen Chemicals Limited announced the outcome of its Fund Raising Committee meeting, informing about the allotment of 10,00,000 Equity Shares of face value Rs. 10 each at a price of Rs. 1,610 per Equity Share, including a premium of Rs. 1,600 per Equity Share. The total amount aggregated to ₹161 crore (Rupees One Hundred and Sixty-One Crore only).
The allotment was made on a preferential basis to Cadamba Solutions Private Limited, a Promoter Group Member. This issuance follows a special resolution passed by the company's members at an Extraordinary General Meeting held on March 29, 2026, and has received in-principle approvals from BSE Limited and the National Stock Exchange of India Limited.
The Fund Raising Committee meeting, held on April 18, 2026, commenced at 1:30 p.m. and concluded at 1:40 p.m. Following the allotment, the company's issued, subscribed, and paid-up equity share capital has increased from Rs. 26.38 crore to Rs. 27.38 crore.
The newly allotted equity shares will be listed on BSE Limited and the National Stock Exchange of India Limited and will carry the same rights as existing equity shares, including dividend payments and voting rights. These shares will be subject to a lock-in period as specified under SEBI regulations.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.